AZN Bounce Up SL Hit · -3.5%
Pharmaceuticals
· Bull Market
6/0 Quality
Entry
$94.95
Stop Loss
$91.61
TP1
$101.63
TP2
$104.96
R:R
2.00

Analyst vs AI Verdict

Wall Street

80.6% Buy Rating
12
Strong Buy
17
Buy
5
Hold
2
Sell
0
Strong Sell
36 analysts · April 1, 2026

AI Expert Panel

Price Chart

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) 19.8% 19.8% 19.8% 19.8% 21.8% 21.8%
P/E (TTM) 25.45 29.72 28.13 30.84 30.10 30.65
Net Margin 17.0% 14.7% 14.7% 14.7% 16.2% 16.2%
Gross Margin 82.0% 82.1% 82.1% 82.1% 81.9% 81.9%
D/E Ratio 73.43 73.43 73.43 73.43 71.11 71.11
Current Ratio 0.86 0.86 0.86 0.86 0.88 0.88

Company Summary

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

View full stock profile →

Trade Outcome

Exit Price $91.61
Profit -3.5%
Hold Time 11 days
Max Price $96.43
Exit Reason sl_hit

Context Synthesis

1/2 Bullish
Analysts
80.6% Buy
Earnings Beat
50.0%
Full analysis →

Historical Stats

AZN Bounce Up

Total Attempts 6
Hit SL 2
Expired 4
Win Rate 0.0%
Last Outcome Time

Signal Info

Created Jan 09, 2026 00:00
Updated Jan 20, 2026 16:00
Market Bull
Timeout 90 days

Disclaimer: This is an automated trading signal generated by AI analysis. It is not financial advice. Always do your own research before making investment decisions. Past performance does not guarantee future results.